Inhibition of nasopharyngeal carcinoma growth by RTA-expressing baculovirus vectors containing oriP

Journal of Gene Medicine

Volumn 10, Issue 10, 2008, Pages 1124-1133

  Wang, Leyao ^a   Shan, Liang ^a   Lo, Kwok Wai ^b   Yin, Juan ^a   Zhang, Yuanyuan ^a   Sun, Ren ^c   Zhong, Jiang ^a  

^a FUDAN UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Baculovirus vector; Epstein Barr virus; Gene therapy; Nasopharyngeal carcinoma; OriP EBNA 1; RTA

Indexed keywords

BACULOVIRUS VECTOR; EPSTEIN BARR VIRUS ANTIGEN; IMMEDIATE EARLY PROTEIN BZLF1; LATENT REPLICATION ORIGIN PROTEIN; ONCOPROTEIN; UNCLASSIFIED DRUG; BRLF1 PROTEIN, HUMAN HERPESVIRUS 4; IMMEDIATE EARLY PROTEIN; TRANSACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; FEMALE; GENE CASSETTE; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION; ANIMAL; BACULOVIRUS; CARCINOMA; CELL LINE; DNA REPLICATION ORIGIN; EPSTEIN BARR VIRUS; FLUORESCENCE MICROSCOPY; GENE THERAPY; GENE VECTOR; GENETICS; METABOLISM; NASOPHARYNX TUMOR; NUDE MOUSE; VIROLOGY; VIRUS INFECTION; VIRUS LATENCY;

HUMAN HERPESVIRUS 4; MUS MUSCULUS;

ANIMALS; BACULOVIRIDAE; CARCINOMA; CELL LINE; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GENE THERAPY; GENETIC VECTORS; HERPESVIRUS 4, HUMAN; IMMEDIATE-EARLY PROTEINS; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NASOPHARYNGEAL NEOPLASMS; REPLICATION ORIGIN; TRANS-ACTIVATORS; VIRUS LATENCY; VIRUS REPLICATION;

EID: 58149184700     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1237     Document Type: Article

References (41)

1. Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 2003; 22: 5108-5121.
2. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4: 757-768.
3. Sam CK, Brooks LA, Niedobitek G, Young LS, Prasad U, Rickinson AB. Analysis of Epstein-Barr virus infection in nasopharyngeal biopsies from a group at high risk of nasopharyngeal carcinoma. Int J Cancer 1993; 53: 957-962.
4. Yates JL, Guan N. Epstein-Barr virus-derived plasmids replicate only once per cell cycle and are not amplified after entry into cells. J Virol 1991; 65: 483-488.
5. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985; 313: 812-815.
6. Rawlins DR, Milman G, Hayward SD, Hayward GS. Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell 1985; 42: 859-868.
7. Chen MR, Middeldorp JM, Hayward SD. Separation of the complex DNA binding domain of EBNA-1 into DNA recognition and dimerization subdomains of novel structure. J Virol 1993; 67: 4875-4885.
8. Marechal V, Dehee A, Chikhi-Brachet R, Piolot T, Coppey-Moisan M, Nicolas JC. Mapping EBNA-1 domains involved in binding to metaphase chromosomes. J Virol 1999; 73: 4385-4392.
9. Langle-Rouault F, Patzel V, Benavente A, et al. Up to 100-fold increase of apparent gene expression in the presence of Epstein-Barr virus OriP sequences and EBNA-1: implications of the nuclear import of plasmids. J Virol 1998; 72: 6181-6185.
10. Reisman D, Sugden B. Trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. Mol Cell Biol 1986; 6: 3838-3846.
11. Shan L, Wang L, Yin J, Zhong P, Zhong J. An OriP/EBNA-1-based baculovirus vector with prolonged and enhanced transgene expression. J Gene Med 2006; 8: 1400-1406.
12. Nasimuzzaman M, Kuroda M, Dohno S. Eradication of Epstein-Barr virus episome and associated inhibition of infected tumor cell growth by adenovirus vector-mediated transduction of dominant-negative EBNA-1. Mol Ther 2005; 11: 578-590.
13. Feng WH, Westphal E, Mauser A, et al. Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors. J Virol 2002; 76: 10951-10959.
14. Rooney C, Rowe D, Ragot T, Farrell PJ. The spliced BZLF1 gene of Epstein-Barr virus transactivates an early EBV promoter and induces the lytic productive cycle. J Virol 1989; 63: 3109-3116.
15. Ragoczy T, Heston L, Miller G. The Epstein-Barr virus RTA protein disrupts latency in B lymphocytes. J Virol 1998; 72: 7978-7984.
16. Hofmann C, Sandig V, Jennings G, Rudolph M, Schlag P, Strauss M. Efficient gene-transfer into human hepatocytes by baculovirus vectors. Proc Natl Acad Sci USA 1995; 92: 10099-10103.
17. Shoji I, Aizaki H, Tani H, et al. Efficient gene transfer into various mammalian cells, including non-hepatic cells, by baculovirus vectors. J Gen Virol 1997; 78: 2657-2664.
18. Condreay JP, Witherspoon SM, Clay WC, Kost TA. Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector. Proc Natl Acad Sci USA 1999; 96: 127-132.
19. Sarkis C, Serguera C, Petres S, et al. Efficient transduction of neural cells in vitro and in vivo by a baculovirus-derived vector. Proc Natl Acad Sci USA 2000; 97: 14638-14643.
20. Hu YC. Baculovirus vectors for gene therapy. Adv Virus Res 2006; 68: 287-320.
21. Wang CY, Li F, Yang Y, Guo HY, Wu CX, Wang S. Recombinant baculovirus containing the diphtheria toxin A gene formalignant glioma therapy. Cancer Res 2006; 66: 5798-5806.
22. Kim CH, Yoon JS, Sohn HJ, et al. Direct vaccination with pseudotype baculovirus expressing murine telomerase induces anti-tumor immunity comparable with RNA-electroporated dendritic cells in a murine glioma model. Cancer Lett 2007; 250: 276-283.
23. Abe T, Takahashi H, Hamazaki H, Miyano-Kurosaki N, Matsuura Y, Takaku H. Baculovirus induces an innate immune response and confers protection from lethal influenza virus infection in mice. J Immunol 2003; 171: 1133-1139.
24. Raty JK, Liimatainen T, Huhtala T, et al. SPECT/CT imaging of baculovirus biodistribution in rat. Gene Ther 2007; 14: 930-938.
25. Rickabaugh TM, Brown HJ, Wu TT, et al. Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 RTA reactivates murine gammaherpesvirus 68 from latency. J Virol 2005; 79: 3217-3222.
26. Lo AK, Lo KW, Tsao SW, et al. Epstein-Barr virus infection alters cellular signal cascades in human nasopharyngeal epithelial cells. Neoplasia 2006; 8: 173-180.
27. Cheung ST, Huang DP, Hui AB, et al. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer 1999; 83: 121-126.
28. Glaser R, Zhang HY, Yao KT, et al. Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. Proc Natl Acad Sci USA 1989; 86: 9524-9528.
29. Baujat B, Audry H, Bourhis J, et al. Chemotherapy as an adjunct to radiotherapy in locally advanced nasopharyngeal carcinoma. Cochrane Database Syst Rev 2006; 4: CD004329.
30. Steel GG. The search for therapeutic gain in the combination of radiotherapy and chemotherapy. Radiother Oncol 1988; 11: 31-53.
31. Wang L, Shan L, Yin J, Zhao M, Su D, Zhong J. The activation of lytic replication of Epstein-Barr virus by baculovirus-mediated gene transduction. Arch Virol 2006; 151: 2047-2053.
32. Swenson J, Mauser A, Kaufmann W, Kenney SC. The Epstein-Barr virus protein BRLF1 activates S phase entry through E2F1 induction. J Virol 1999; 73: 6540-6550.
33. Kudoh A, Fujita M, Zhang L, et al. Epstein-Barr virus lytic replication elicits ATM checkpoint signal transduction while providing an S-phase-like cellular environment. J Biol Chem 2005; 280: 8156-8163.
34. Henderson SD, Huen M, Rowe C, Dawson C, Johnson G, Rickinson A. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc Natl Acad Sci USA 1993; 90: 8479-8483.
35. Sheng W, Decaussin G, Sumner S, Ooka T. N-terminal domain of BARF1 gene encoded by Epstein-Barr virus is essential for malignant transformation of rodent fibroblasts and activation of BCL-2. Oncogene 2001; 20: 1176-1185.
36. Inman GJ, Binné UK, Parker GA, Farrell PJ, Allday MJ. Activators of the Epstein-Barr virus lytic program concomitantly induce apoptosis, but lytic gene expression protects from cell death. J Virol 2001; 75: 2400-2410.
37. Cayrol C, Flemington EK. The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors. EMBO J 1996; 15: 2748-2759.
38. Nilsson T, Zetterberg H, Wang YC, Rymo L. Promoterproximal regulatory elements involved in OriP-EBNA-1-independent and -dependent activation of the Epstein-Barr virus C promoter in B-lymphoid cell lines. J Virol 2001; 75: 5796-5811.
39. Kang MS, Hung SC, Kieff E. Epstein-Barr virus nuclear antigen 1 activates transcription from episomal but not integrated DNA and does not alter lymphocyte growth. Proc Natl Acad Sci USA 2001; 98: 15233-15238.
40. Wilson JB, Bell JL, Levine AJ. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J 1996; 15: 3117-3126.
41. Kennedy G, Komano J, Sugden B. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. Proc Natl Acad Sci USA 2003; 100: 14269-14274.